41 results
8-K
EX-99.1
KA
Kineta Inc
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
Exhibit 99.1
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th … -CD27 agonist monoclonal antibodies (mAbs) at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief
8-K
EX-99.1
KA
Kineta Inc
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
takeaways from the recent European Society for Medical Oncology Immuno-Oncology Congress (ESMO) and Society for Immunotherapy of Cancer (SITC) Annual
8-K
EX-99.1
KA
Kineta Inc
7 Jun 17
Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs
12:00am
European Cystic Fibrosis Society Conference
CAMBRIDGE, Mass. – June 7, 2017 – Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a biopharmaceutical company … Society conference in Seville, Spain, where the Company is presenting detailed results from the single ascending dose (SAD) cohort of its Phase 1 trial
8-K
EX-99.1
KA
Kineta Inc
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
Exhibit 99.1
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th … -101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors at the Society
8-K
EX-99
KA
Kineta Inc
11 Dec 19
Other Events
7:15am
Fibrosis Society Clinical Trial Network(ECFS-CTN), which is recruiting adult CF patients into theex- vivostudy through its 43 clinical trial centers.HIT-CF … a participating pharmaceutical company.
All participating centers are part of the European Cystic Fibrosis Society – Clinical Trial Network(ECFS-CTN
425
6lpbc17rx8p9dibe9p
29 Nov 22
Business combination disclosure
4:03pm
8-K
f5s4iao 2ibenuy
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
2x05tgpbeo
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
425
rv2306fbqydalb8n2
27 Oct 22
Business combination disclosure
7:15am
8-K
EX-99.1
4du0ur7vc1qp
27 Oct 22
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
7:13am
8-K
3cx6ezi phkz
11 Dec 19
Other Events
7:15am
8-K
EX-99.1
cuc2xjyj51op5fl6r
22 Jan 20
Proteostasis Therapeutics Announces Keystone Symposia Presentation of
7:00am
8-K
EX-99.1
sll0o7em
7 Aug 19
Proteostasis Therapeutics Reports Second Quarter 2019 Financial Results
4:05pm
8-K
EX-99.1
m0bkiu4fn5
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
5z3at
15 May 20
Proteostasis Therapeutics Reports First Quarter 2020 Financial Results
4:11pm
8-K
j3q5611
27 Oct 22
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
7:13am
8-K
EX-99.1
q5hg6 q0b
12 Aug 21
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
pnxtrd04
13 May 21
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
4:00pm
8-K
EX-99.1
60knqj4157e mb
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
3jv31yieuw0f4
3 Oct 18
Regulation FD Disclosure
8:01am